title: Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells.
authors.forename: E K
authors.initials: EK
authors.lastname: Allan
authors.forename: A
authors.initials: A
authors.lastname: Hamilton
authors.forename: S
authors.initials: S
authors.lastname: Hatziieremia
authors.forename: P
authors.initials: P
authors.lastname: Zhou
authors.forename: H G
authors.initials: HG
authors.lastname: Jørgensen
authors.forename: P
authors.initials: P
authors.lastname: Vigneri
authors.forename: T L
authors.initials: TL
authors.lastname: Holyoake
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D001549:Benzamides; D002467:Cell Nucleus / Q000378:metabolism*; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism*; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D001549:Benzamides; D005231:Fatty Acids, Unsaturated; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C038753:leptomycin B